Oncology News | pharmaphorum

News

FDA starts swift review of Regeneron’s CD20 bispecific

The FDA has started a priority review of Regeneron’s CD20xCD3 bispecific antibody odronextamab, seeking a broader label than other drugs in the class.

News

Rare womb cancer is a women’s health success story

Imagine being told just after giving birth to a new baby that you have cancer.

News

J&J doublet beats Tagrisso in first-line lung cancer

AstraZeneca’s Tagrisso could face some serious competition as a first-line targeted therapy for advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC), in

News

Novartis eyes first-line use of Lutathera after trial win

Novartis is preparing to file for approval of its radioligand therapy Lutathera as a first-line treatment for people with rare neuroendocrine tumours after it showed a ben

News

Seagen hails ‘practice-changing’ trial in bladder cancer

A combination of Astellas and Seagen’s Padcev with MSD’s Keytruda has significantly improved survival compared to chemotherapy in previously untreated patients with advanc

News

AZ, Daiichi Sankyo cue up TROP2 drug filing in breast cancer

Armed with the first phase 3 data for their TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan as a second-line treatment for breast cancer, AstraZeneca

FDA starts swift review of Regeneron’s CD20 bispecific

Rare womb cancer is a women’s health success story

J&J doublet beats Tagrisso in first-line lung cancer

Novartis eyes first-line use of Lutathera after trial win

Seagen hails ‘practice-changing’ trial in bladder cancer

AZ, Daiichi Sankyo cue up TROP2 drug filing in breast cancer

Pulmonary fibrosis drug developer Avalyn files IPO

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks